Drug Profile
Research programme: voltage-gated sodium channel inhibitors - Merck
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Amides; Biphenyl compounds; Pyrazoles
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (PO)
- 26 Aug 2010 Pharmacodynamics and pharmacokinetics data from preclinical studies in rodents presented at the 240th American Society National Meeting (240th-ACS-2010)
- 05 Sep 2007 Preclinical data presented at the 234th American Chemical Society National Meeting (234th-ACS-2007) added to the pharmacokinetics section